|Offre||74,76 x 1000|
|Vente||74,80 x 1200|
|Var. jour||74,58 - 75,75|
|Sur 52 semaines||61,45 - 89,74|
|Volume moyen||5 471 366|
|Bêta (mensuel sur 5 ans)||0,39|
|Rapport P/E (sur 12 mois)||17,20|
|BPA (sur 12 mois)||4,35|
|Date de bénéfices||25 oct. 2023 - 30 oct. 2023|
|Dividende et rendement à terme||3,00 (3,98 %)|
|Date ex-dividende||14 sept. 2023|
|Objectif sur 1 an||91,04|
NORHAMPTON, MA / ACCESSWIRE / November 10, 2022 / Gilead Sciences While Jesse Garcia was growing up in Chicago's inner city, his parents didn't immediately turn to a doctor when someone in the family got sick. "We relied on traditional Latino ...
NORTHAMPTON, MA / ACCESSWIRE / November 2, 2022 / Gilead Sciences Since the beginning of the COVID-19 pandemic, Gilead's first-in-class antiviral was made available to more than 11 million patients globally- over 65% of whom live in low-and lower-middle-income ...
In the spring of 2018, North Carolina native Stephanie Walker went to her first breast cancer conference and had a revelation that she refers to as her "coming-out party." She learned she had metastatic breast cancer three years earlier and although she was a retired hospice nurse, she faced the disease without any guidance from others who shared her experience.